CHRS
Price
$0.78
Change
-$0.04 (-4.88%)
Updated
Nov 13 closing price
105 days until earnings call
OGEN
Price
$0.34
Change
-$0.02 (-5.56%)
Updated
Nov 13 closing price
Ad is loading...

CHRS vs OGEN

Header iconCHRS vs OGEN Comparison
Open Charts CHRS vs OGENBanner chart's image
Coherus BioSciences
Price$0.78
Change-$0.04 (-4.88%)
Volume$2.37M
CapitalizationN/A
Oragenics
Price$0.34
Change-$0.02 (-5.56%)
Volume$320.02K
CapitalizationN/A
CHRS vs OGEN Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CHRS vs. OGEN commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and OGEN is a Hold.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (CHRS: $0.78 vs. OGEN: $0.34)
Brand notoriety: CHRS and OGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 85% vs. OGEN: 70%
Market capitalization -- CHRS: $89.75M vs. OGEN: $3.83M
CHRS [@Biotechnology] is valued at $89.75M. OGEN’s [@Biotechnology] market capitalization is $3.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileOGEN’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • OGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, OGEN is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 6 TA indicator(s) are bullish while OGEN’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 6 bullish, 2 bearish.
  • OGEN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than OGEN.

Price Growth

CHRS (@Biotechnology) experienced а +7.63% price change this week, while OGEN (@Biotechnology) price change was +8.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.97%. For the same industry, the average monthly price growth was +5.49%, and the average quarterly price growth was +6.49%.

Reported Earning Dates

CHRS is expected to report earnings on Feb 27, 2025.

OGEN is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Biotechnology (-1.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($89.8M) has a higher market cap than OGEN($3.83M). CHRS YTD gains are higher at: -76.607 vs. OGEN (-93.957). CHRS has higher annual earnings (EBITDA): 12.3M vs. OGEN (-19.48M). CHRS has more cash in the bank: 159M vs. OGEN (1.35M). OGEN has less debt than CHRS: OGEN (0) vs CHRS (270M). CHRS has higher revenues than OGEN: CHRS (308M) vs OGEN (0).
CHRSOGENCHRS / OGEN
Capitalization89.8M3.83M2,346%
EBITDA12.3M-19.48M-63%
Gain YTD-76.607-93.95782%
P/E RatioN/AN/A-
Revenue308M0-
Total Cash159M1.35M11,787%
Total Debt270M0-
FUNDAMENTALS RATINGS
CHRS vs OGEN: Fundamental Ratings
CHRS
OGEN
OUTLOOK RATING
1..100
565
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9366
P/E GROWTH RATING
1..100
69100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGEN's Valuation (65) in the Biotechnology industry is in the same range as CHRS (91). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

OGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

OGEN's SMR Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

OGEN's Price Growth Rating (66) in the Biotechnology industry is in the same range as CHRS (93). This means that OGEN’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's P/E Growth Rating (69) in the Biotechnology industry is in the same range as OGEN (100). This means that CHRS’s stock grew similarly to OGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSOGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HII204.00-0.60
-0.29%
Huntington Ingalls Industries
SMECF432.00-2.90
-0.67%
SMC Corp
ALLT3.74-0.17
-4.35%
Allot Ltd
RKT14.13-1.41
-9.07%
Rocket Companies
VERV5.79-0.62
-9.67%
Verve Therapeutics

OGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGEN has been loosely correlated with ATHA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OGEN jumps, then ATHA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGEN
1D Price
Change %
OGEN100%
-6.59%
ATHA - OGEN
34%
Loosely correlated
-8.75%
SRPT - OGEN
30%
Poorly correlated
-1.61%
CHRS - OGEN
27%
Poorly correlated
-5.40%
RVNC - OGEN
26%
Poorly correlated
+2.91%
RNA - OGEN
26%
Poorly correlated
+12.45%
More